SEC Comment Letter for 20 (AIDX) — Jul 15, 2020

20/20 Biolabs, Inc. (AIDX) (CIK 0001139685)
Date: July 15, 2020 · CIK: 0001139685 · Accession: 0000000000-20-006447

View on Edgar

AI Filing Summary & Sentiment

Sentiment

Urgency

Document Type

Confidence

SEC Posture

Company Posture

Summary

Reasoning

File numbers found in text: 024-11056

Date

July 15, 2020

Author

Jonathan Cohen

Form

UPLOAD

Company

20/20 Biolabs, Inc. (AIDX) (CIK 0001139685)

Letter

United States securities and exchange commission logo July 15, 2020 Jonathan Cohen Chief Executive Officer and President 20/20 GeneSystems, Inc. 9430 Key West Ave. Rockville, MD 20850 Re:20/20 GeneSystems, Inc. Offering Statement on Form 1-A Post-Qualification Amendment No. 1 Filed July 8, 2020 File No. 024-11056 Dear Mr. Cohen: We have reviewed your amendment and do not have any comments. We will consider qualifying your offering statement at your request. If a participant in your offering is required to clear its compensation arrangements with FINRA, please have FINRA advise us that it has no objections to the compensation arrangements prior to qualification. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Cara Wirth at (202) 551-7127 or Erin Jaskot at (202) 551-3442 with any questions. Sincerely, Division of Corporation Finance Office of Trade & Services cc: Louis A. Bevilacqua, Esq.

Show Raw Text

United States securities and exchange commission logo
July 15, 2020
Jonathan Cohen
Chief Executive Officer and President
20/20 GeneSystems, Inc.
9430 Key West Ave.
Rockville, MD 20850
Re:20/20 GeneSystems, Inc.
Offering Statement on Form 1-A
Post-Qualification Amendment No. 1
Filed July 8, 2020
File No. 024-11056
Dear Mr. Cohen:
            We have reviewed your amendment and do not have any comments.
            We will consider qualifying your offering statement at your request.  If a participant in
your offering is required to clear its compensation arrangements with FINRA, please have
FINRA advise us that it has no objections to the compensation arrangements prior to
qualification.
            We remind you that the company and its management are responsible for the accuracy
and adequacy of their disclosures, notwithstanding any review, comments, action or absence of
action by the staff.
            Please contact Cara Wirth at (202) 551-7127 or Erin Jaskot at (202) 551-3442 with any
questions.
Sincerely,
Division of Corporation Finance
Office of Trade & Services
cc:       Louis A. Bevilacqua, Esq.

SecProbe.io